L Catterton leads $27m Series B round in Chinese synthetic collagen developer

L Catterton leads $27m Series B round in Chinese synthetic collagen developer

Trautec Medical Technology's synthetic recombinant human collagen products. Source: Trautec.

28 September, 2023

Edited by: Padma Priya

Boyu Capital L Catterton Shiseido Trautec Medical Technology

Printed by Unregistered user on Tue, 09 Sep 2025 17:21:44 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

L Catterton adds Japanese veterinary services group Withmal to its portfolio

L Catterton forays into India's pet food sector with $60m investment in Drools

Read more from Greater China

China’s M&A value to hit ‘double-digit growth’ in 2025 on strategic sales

Venture Capital

Alibaba Cloud anchors X Square’s $140m round in embodied AI push